Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Phase observationalN = 58
- Population
- Patients with HCV infection and a history of treated hepatocellular carcinoma with complete response and no non-characterised nodules at the start of all-oral DAA therapy; 103 patients with prior HCC received DAA and 58 met the inclusion criteria.
- Design
- Multicentre (4 hospitals) cohort of patients with HCV infection and prior treated hepatocellular carcinoma in complete response who received all-oral direct-acting antivirals between 2014 and 2015; interferon-containing regimens excluded. Single group; no control arm.
- Arms
- DAA after treated HCC (experimental, n = 58): All-oral direct-acting antiviral therapy (interferon excluded)
- People
- Reig M
Show the numbers
| Endpoint | Analysis | DAA after treated HCC | Control | Effect |
|---|---|---|---|---|
| Radiological tumour recurrence58 patients meeting the inclusion criteriaRadiologic tumour recurrence during follow-up in people with prior treated HCC. | primarymedian follow-up 5.7 monthsReig 2016 | 27.6% | — | 16 patients developed radiologic tumour recurrence after a median follow-up of 5.7 months; 3 patients died. The authors describe the cohort as very small. |
| Endpoint | Analysis | DAA after treated HCC | Control | Effect |
|---|---|---|---|---|
| Radiological tumour recurrence58 patients meeting the inclusion criteriaRadiologic tumour recurrence during follow-up in people with prior treated HCC. | primarymedian follow-up 5.7 monthsReig 2016 | 27.6% | — | 16 patients developed radiologic tumour recurrence after a median follow-up of 5.7 months; 3 patients died. The authors describe the cohort as very small. |